Form 4: UTHR President & COO Exercises Options, Sells Shares

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold common stock shares totaling over $10 million, all under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), engaged in transactions on November 3, 2025.
• Exercised stock options to acquire 14,625 shares of common stock at an exercise price of $135.42 per share.
• Exercised stock options to acquire an additional 7,875 shares of common stock at an exercise price of $146.03 per share.
• Sold a total of 14,625 shares of common stock (resulting from the first option exercise) at weighted average prices ranging from $432.5476 to $441.9446 per share.
• Sold a total of 7,875 shares of common stock (resulting from the second option exercise) at a weighted average price of $417.4965 per share.
• Disposed of an additional 2,648 shares of common stock.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
• The shares are held indirectly by trusts where Benkowitz is a beneficiary or has investment/voting power.

Sentiment

Score: 5

Explanation: The transactions involve significant insider selling, which could be seen as slightly negative. However, the execution under a Rule 10b5-1 plan mitigates the negative signal, making it a largely neutral event as it's a pre-planned diversification or liquidity event rather than a reaction to new, negative information. The exercise of options also reflects the executive realizing value from past compensation.

Positives

• The executive exercised stock options, indicating a realization of value from previously granted equity compensation.
• Transactions were conducted under a Rule 10b5-1 trading plan, which demonstrates pre-planning and reduces concerns about opportunistic insider trading.

Negatives

• Significant insider selling of common stock occurred, which can sometimes be interpreted as a lack of confidence, although mitigated by the 10b5-1 plan.
• The total value of shares sold exceeded $10 million, representing a substantial reduction in the executive's direct common stock holdings.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's equity compensation management.

Related Party Transactions

• The shares are held indirectly by trusts where the Reporting Person is a beneficiary, co-trustee with shared investment and voting power, or where family members are beneficiaries and the Reporting Person has sole investment and voting power. These are considered related party dealings for reporting purposes.

Stakeholder Impact

• Shareholders: The sale of shares by a high-ranking executive could be perceived as a slight negative signal, though the 10b5-1 plan mitigates this. It does not directly impact the company's operations or financial performance.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Recommendation

The filing details routine insider transactions executed under a pre-arranged 10b5-1 plan. While there is significant insider selling, the pre-planned nature means it does not convey new information about the company's fundamentals or future prospects. Therefore, it is unlikely to significantly alter the investment thesis for UTHR, warranting a 'hold' recommendation based solely on this filing.

Keywords

United Therapeutics, UTHR, Michael Benkowitz, Insider Trading, Form 4, Stock Options, Equity Sales, 10b5-1 Plan, Executive Compensation